Sai Life Sciences adopts FY26 results at 27th AGM
- Sai Life Sciences shareholders adopted FY26 standalone and consolidated financial statements
- Mr. Krishnam Raju Kanumuri was re-appointed as director after retiring by rotation
- The 27th AGM was held on September 17, 2026, via video conferencing
- Auditor’s report contained no qualifications or adverse comments on financials

*this image is generated using AI for illustrative purposes only.
Sai Life Sciences shareholders adopted the audited standalone and consolidated financial statements for FY26 at the company’s 27th Annual General Meeting (AGM). The meeting was held on September 17, 2026, via video conferencing.
The event transacted ordinary business items as outlined in the notice. Shareholders also approved the re-appointment of Mr. Krishnam Raju Kanumuri as a director, replacing himself upon retirement by rotation.
Meeting Proceedings
The AGM commenced at 10:30 am with Dr. Kanumuri Ranga Raju, Chairman and Whole Time Director, calling the meeting to order. Due to technical issues, Mr. Sivaramakrishnan Chittor, Whole-Time Director and Chief Financial Officer, addressed the shareholders on behalf of Mr. Krishnam Raju Kanumuri, Managing Director and Chief Executive Officer.
Mr. Chittor presented an overview of the company’s financial performance for FY26. He highlighted key operational achievements and outlined the growth strategy expected to drive value creation for stakeholders.
Key Attendees
The following directors were present at the meeting:
- Dr. Kanumuri Ranga Raju, Chairman & Whole Time Director
- Mr. Krishnam Raju Kanumuri, Managing Director & CEO
- Mr. Sivaramakrishnan Chittor, Whole-time Director & CFO
- Mr. Dinesh Vinoobhai Patel, Independent Director
- Mr. Ramesh Ganesh Iyer, Independent Director
- Ms. Suchita Sharma, Independent Director
Ms. Runa Karan, Company Secretary & Compliance Officer, welcomed members and confirmed compliance with Ministry of Corporate Affairs and SEBI circulars regarding virtual meetings.
Voting and Compliance
The company provided remote e-voting facilities through KFin Technologies Limited from September 14 to September 16, 2026. Mr. DSM Ram was appointed as the scrutinizer for the voting process.
Members holding 7,76,98,047 equity shares participated in the meeting. The auditor’s report contained no qualifications, observations, or adverse comments on the financial statements. Similarly, the secretarial audit report had no adverse remarks.
The meeting concluded at 11:25 am after all resolutions were passed with the requisite majority.
Historical Stock Returns for Sai Life Sciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.13% | -8.02% | +6.29% | +57.82% | +74.86% | +101.54% |
What specific growth strategies did Mr. Chittor outline during the AGM that are expected to drive value creation for stakeholders in the upcoming fiscal year?
How might the clean auditor and secretarial audit reports influence investor confidence and the company's credit rating in the near term?
Given the high participation of 7.76 crore equity shares, what does this level of shareholder engagement suggest about sentiment regarding Sai Life Sciences' future direction?


































